Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Device Accessibility Complaints To Be Monitored By CMS Ombudsman

This article was originally published in The Gray Sheet

Executive Summary

CMS ombudsman Dan Schreiner will report annually to Congress on the agency's performance in addressing beneficiary concerns, as stipulated by the Medicare Modernization Act (MMA)

You may also be interested in...

People In Brief

FDA Deputy Commissioner for Policy: Amit Sachdev leaves the agency to pursue private-sector opportunities after serving more than eight years in various government positions and roughly a year at one of the three deputy-commissioner posts created by Acting Commissioner Lester Crawford in the top-level restructuring that followed Mark McClellan's 2004 departure. As FDA's legislative liaison, Sachdev was involved with MDUFMA (1"The Gray Sheet" Sept. 23, 2002, p. 4). Crawford's confirmation as FDA's permanent chief could create another opportunity to revisit its leadership structure...

Surging China Coronavirus Trials Prompt Tougher Criteria

A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules. 

Perrigo Reports Broad Growth, But Investors Sour On Turnaround's Price Tag

Its reported worldwide consumer Q4 net sales increased 12.7%, or 16.4% adjusted for currency exchange rates, product launches and other changes from the prior-year period, to $1.1bn. The s results, though, sent share price plummeting $8.64, more than 14%, to $51.82.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts